Skip to content

Causal Role of Delta and Theta Oscillations in Hierarchical Cognitive Control

Causal Role of Delta and Theta Oscillations in Hierarchical Cognitive Control

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06734377
Enrollment
66
Registered
2024-12-16
Start date
2025-01-20
Completion date
2025-10-17
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhythmic Transcranial Magnetic Stimulation (rTMS) Effect on Hierarchical Cognitive Control

Keywords

Rhythmic Transcranial Magnetic Stimulation, Hierarchical Cogntive Control

Brief summary

The purpose of this clinical trial is to evaluate the effect of rhythmic transcranial magnetic stimulation (TMS) delivered at delta (2.2 Hz) or theta (6.5 Hz) frequency on cognitive control. This study aims to explore how targeted stimulation at delta and theta frequencies modulates brain activity to enhance cognitive performance in healthy populations.

Detailed description

Neural oscillations are proposed to be a mechanism of coordinating information processing across distributed regions of cortex. Different neural oscillations may correspond to different underlying neural computations. Noninvasive brain stimulation allows experimenters to modulate specific neural oscillations by targeting particular frequency bands. Rhythmic transcranial magnetic stimulation (TMS) has been previously demonstrated to entrain neural oscillations at the frequency of stimulation. Previous evidence suggests that cognitive control task paradigms elicit distinct activity in both Delta band (2-3 Hz) and Theta band (4-7 Hz). This task is designed to examine hierarchical cognitive control and includes two subtasks. In the Response Task, participants see a colored fixation cross and must make a button press with a specific finger. The stimulus to response mapping is memorized ahead of time. The number of stimulus to response rules is manipulated as four (low set-size) or eight (high set-size). In the Dimension Task, participants see two objects and must judge whether they are the same or different depending on one of two features. One feature is the shape of the object as either tall or wide. The other feature is the complexity of the objects as either being simple and smooth or complex and multifaceted. In this task, delta oscillations (2-3 Hz) are associated with rule abstraction, engaging the mid-dorsolateral prefrontal cortex (mid-dlPFC), while theta oscillations (4-7 Hz) are linked to stimulus-action associations and working memory load, with increased theta activity observed in the dorsal premotor area (PMd) under high set-size conditions. For the current study, the investigators propose to deliver rhythmic trains of TMS in either delta frequency, theta frequency, or an arrhythmic control to modulate neural processing during a cognitive control task. By collecting simultaneous EEG with TMS, the investigators will be able to measure the entrained oscillations from rhythmic TMS. By applying delta frequency, theta frequency, and arrhythmic TMS during the performance of the task at each location, the investigators will be able to examine the causal relationship of delta oscillations at mid-dlPFC in rule abstraction and theta oscillations at PMd in stimulus-action associations. The stimulation is designed to enhance task performance by amplifying the neural activity patterns observed under these conditions.

Interventions

DEVICEDelta TMS

TMS will be administered at the frequency of delta oscillation (2.2Hz)

DEVICETheta TMS

TMS will be administered at the frequency of theta oscillation (6.5Hz)

TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency

Sponsors

Florida State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Each participant receives all three types of stimulations (delta, theta, arrhythmic) in both brain regions, with the order of stimulation randomized for each session. Across the 12 task blocks in each session with the stimulation, the type of stimulation is interleaved, ensuring that all conditions are represented in a balanced manner. The number of trials for each stimulation condition is counterbalanced within and across blocks to provide equal exposure to each type.

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must be between the ages of 18 and 35. * Must be able to provide informed consent. * Must have normal or corrected-to-normal vision. * Participants must be right-handed. * Willingness to comply with all study procedures and availability for the study duration. * Proficiency in speaking and understanding English.

Exclusion criteria

* Must not be color-blind * Current treatment for ADHD/ADD. * History of neurological disorders, including but not limited to the following specified conditions * Epilepsy or seizures (excluding childhood febrile seizures). * Dementia, Parkinson's disease, multiple sclerosis, cerebral aneurysm, or brain tumors. * History of stroke or traumatic brain injury. * Medical conditions or treatments that could interfere with study participation (e.g., unstable cardiac disease, HIV/AIDS, malignancy, or renal impairment). * Prior brain surgery or presence of brain devices/implants (e.g., cochlear implants or aneurysm clips). * Females who are pregnant or breastfeeding. * Use of specific medications, including but not limited to ADHD medications or benzodiazepines, which may interfere with EEG measurements or task performance * Any condition that, in the opinion of the investigator, increases risk or hinders full compliance with the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in AccuracyBaseline (week 1); Session 1 (week 2); Session 2 (week 3)The Accuracy, reflecting the participants' ability to correctly follow task rules and make accurate judgments based on the given stimulus, is calculated as the percentage of correct responses across trials. The value range is 0% (no correct responses) to 100% (all responses correct), with a larger number denoting more correct responses.

Secondary

MeasureTime frameDescription
Change in Response TimeBaseline (week 1); Session 1 (week 2); Session 2 (week 3)The Response Time (RT), reflects the time taken by participants to respond to stimuli during the task. The value range is 0 seconds to 2 seconds, with a smaller number denoting faster responses.
Change in Amplitude of Neural Oscillations in mid-dlPFCBaseline (week 1); Session 1 (week 2); Session 2 (week 3)The electrical activity of the brain is recorded during the performance of the task and brain stimulation. The investigators will perform Morlet wavelet convolution on the recorded electrical signal to calculate the amplitude of neural oscillations in the frequency bands: Delta (2-3 Hz) and Theta (4-7 Hz). The amplitude of neural oscillations is reported in the region that is being stimulated. The change in amplitude is normalized for each participant as the percent change from the amplitude during the baseline compared to the stimulation session (Session 1 or Session 2).
Change in Amplitude of Neural Oscillations in PMdBaseline (week 1); Session 1 (week 2); Session 2 (week 3)The electrical activity of the brain is recorded during the performance of the task and brain stimulation. The investigators will perform Morlet wavelet convolution on the recorded electrical signal to calculate the amplitude of neural oscillations in the frequency bands: Delta (2-3 Hz) and Theta (4-7 Hz). The amplitude of neural oscillations is reported in the region that is being stimulated. The change in amplitude is normalized for each participant as the percent change from the amplitude during the baseline compared to the stimulation session (Session 1 or Session 2).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026